Stocks and Investing
Stocks and Investing
Wed, May 25, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, May 24, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Salveen Richter Maintained (AGIO) at Strong Sell with Decreased Target to $16 on, May 24th, 2022
Salveen Richter of Goldman Sachs, Maintained "Agios Pharmaceuticals, Inc." (AGIO) at Strong Sell with Decreased Target from $20 to $16 on, May 24th, 2022.
Salveen has made no other calls on AGIO in the last 4 months.
There are 4 other peers that have a rating on AGIO. Out of the 4 peers that are also analyzing AGIO, 1 agrees with Salveen's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Andrew Berens of "SVB Leerink" Maintained at Hold with Increased Target to $33 on, Tuesday, May 17th, 2022
These are the ratings of the 3 analyists that currently disagree with Salveen
- Michael King of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $96 on, Thursday, March 3rd, 2022
- Kennen MacKay of "RBC Capital" Maintained at Buy with Increased Target to $67 on, Friday, February 25th, 2022
- John Newman of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $44 on, Wednesday, February 16th, 2022
Contributing Sources